Detalhe da pesquisa
1.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
2.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol
; 96(9): 1120-1130, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34062004
3.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol
; 96(6): 708-718, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33755235
4.
Multiple myeloma triplet therapies: baseline characteristics and control groups - Authors' reply.
Lancet
; 397(10285): 1621-1623, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33933201
5.
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Am J Hematol
; 97(3): E83-E86, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34882831
6.
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
Am J Hematol
; 97(2): E54-E58, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34817872
7.
XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells.
J Cell Physiol
; 231(12): 2711-9, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26991404
8.
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Blood
; 122(17): 3034-44, 2013 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23970380
9.
Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
BMC Vet Res
; 10: 160, 2014 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25022346
10.
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
J Clin Oncol
; 41(35): 5400-5410, 2023 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37669480
11.
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents.
J Hematol Oncol
; 15(1): 103, 2022 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35922861
12.
A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
Clin Cancer Res
; 28(3): 452-460, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34728525
13.
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
EJHaem
; 3(4): 1270-1276, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36467792
14.
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
Clin Lymphoma Myeloma Leuk
; 22(1): 24-33, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34493477
15.
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
Clin Lymphoma Myeloma Leuk
; 22(7): 483-494, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35078739
16.
Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
Antiviral Res
; 192: 105115, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34157321
17.
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
J Hematol Oncol
; 14(1): 111, 2021 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34271963
18.
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
J Hematol Oncol
; 14(1): 59, 2021 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33849608
19.
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Leukemia
; 34(9): 2430-2440, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32094461
20.
Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.
Oncotarget
; 8(47): 82144-82155, 2017 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29137251